The acquisition of Intra-Cellular Therapies by Johnson & Johnson is a strategic move to enhance its portfolio in mental-health drugs, which is expected to drive sales growth beyond analysts' expectations. This positive outlook is likely to boost investor confidence and positively impact JNJ's stock price in the short term.